PN20

Phase 2Small molecule

CChongqing Peg-Bio Biopharm Co., Ltd.

PN20 is one of 78 small molecule programs targeting Immune Thrombocytopenia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Immune ThrombocytopeniaRecruiting

ThrombocytopeniaRecruiting

Immune ThrombocytopeniaPhase 1

Recruiting

ThrombocytopeniaPhase 2

Recruiting

Competition

Competitive Landscape

56 competitors in Immune Thrombocytopenia

#DrugCompanyPhaseTrials

Promacta

GSK

Approved

14 2

Rituxan

Roche

Approved

13 3

Decadron

AAspen Global Incorporated

Approved

21 4

Plaquenil

Jazz Pharmaceuticals

Approved

1 5

Oncovin

Eli Lilly

Approved

1 6

Rayos

RRoxane Laboratories

Approved

6 7

Imuran

LLegacy Health System

Approved

1 8

Doptelet

AAkarx

Phase 3

6 9

Vyvgart

Argenx

Phase 3

6 10

Nublexa

BBeijing InnoCare Pharma Tech Co., Ltd.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Thrombocytopenia2 trials

A Study of PN20 for the Prevention of Chemotherapy-induced Thrombocytopenia in Lymphoma or Solid Tumor Patients

Completed·CChongqing Peg-Bio Biopharm Co., Ltd.·Phase 1·NCT06521931·24 enrolled

A Study to Evaluate the Safety and Efficacy of PN20 in the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing an Elective Procedure

Recruiting·CChongqing Peg-Bio Biopharm Co., Ltd.·Phase 1/2·NCT07446491·54 enrolled

Immune Thrombocytopenia1 trial

Study of PN20 in Adult Patients With Primary Immune Thrombocytopenia (ITP)

Recruiting·CChongqing Peg-Bio Biopharm Co., Ltd.·Phase 1·NCT06880081·12 enrolled

Adult1 trial

A Study of PN20 in Healthy Adult Volunteers

Completed·CChongqing Peg-Bio Biopharm Co., Ltd.·Phase 1·NCT06523088·27 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for PN20. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PN20 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PN20. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Chongqing Peg-Bio Biopharm Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: CChongqing Peg-Bio Biopharm Co., Ltd.

PN20

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Thrombocytopenia2 trials

Immune Thrombocytopenia1 trial

Adult1 trial

References

Drug Info

Quick Facts

Related News